In 2018, a new class of medications was approved by the FDA for the prevention of migraine in adults. These drugs are referred to as calcitonin gene-related peptide (CGRP) inhibitors. There are currently multiple CGRP medications on the market. Dosing, frequency of use and method of action vary.
The financial assistance guide below is for anyone who has been prescribed Emgality by their healthcare provider. Emgality is one of three new CGRP inhibitors approved for the prevention of migraine in adults. If you or someone you know requires help with paying for treatment, review the details provided below to see if you qualify for the manufacturer’s financial assistance programs.
Most insurance companies have added at least one or two CGRP inhibitors to the list of medicines they cover; however, patients still struggle to receive insurance approval for the prescribed CGRP inhibitor. Each pharmaceutical company is offering financial assistance programs to help cover and/or to help cover the cost of high copays. Each program is different and various programs exist to support patients with private, government-funded insurance, as well as the uninsured.
To help patients understand each program, CHAMP created Financial Assistance Guides for all CGRP inhibitors. These guides are not produced or approved by the medication manufacturers. CHAMP is not endorsing the use of any CGRP inhibitor over another, nor promoting the use of this new class of preventive medications for everyone with migraine disease. Every patient needs to consult their healthcare provider to determine if CGRP inhibitors are right for you.
I Have Been Prescribed Emgality.
Find your insurance coverage and see what Financial Assistance Programs exist to help.
Emgality Basics
| Brand Name | Aimovig |
|---|---|
| Biologic Name | galcanezumab-gnlm |
| Pharmaceutical Company | Eli Lilly |
| Website | Emgality.com |
| Helpline | The Emgality Answers Center at 1-833-EMGALITY (1-833-364-2548), Monday through Friday, 9 am-8 pm ET. |
| Injection Training Available | Yes, order a free container at Emgality.lilly.com |
| Full Prescribing Information | Lilly.com (15 page PDF) |
| Dosing & Administration | 300 mg (administered as three consecutive subcutaneous injections of 100 mg each) at the onset of the cluster period, and then monthly until the end of the cluster period. Discuss with your doctor when best to start and end treatment. ou. |
| Indication | Emgality is indicated for the treatment of episodic cluster headache in adults. |
| Sharps Container Available | Yes |
| Home Delivery Available | Emgality does not offer home delivery, however Emgality is available at your local pharmacy. Please call The Emgality Answers Center for more information. |